

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 July 2025 (17.07.2025)



(10) International Publication Number
WO 2025/151135 A1

(51) International Patent Classification:

A61K 38/08 (2019.01) A61K 38/33 (2006.01)
A61K 38/10 (2006.01) A61K 38/34 (2006.01)
A61K 38/12 (2006.01) A61P 35/00 (2006.01)

devica Bio, Inc., 1935 Techny Road, Suite 14, Northbrook, Illinois 60062 (US).

(74) Agent: **FOURNIER, David** et al.; P.O. Box 1247, Seattle, Washington 98111-1247 (US).

(21) International Application Number:

PCT/US2024/016310

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(22) International Filing Date:

16 February 2024 (16.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/618,587 08 January 2024 (08.01.2024) US

(71) Applicant: **ENDEVICA BIO, INC.** [US/US]; 1935 Techny Road, Suite 14, Northbrook, Illinois 60062 (US).

(72) Inventors: **POTTERFIELD, Russell**; 1212 Westmoor Rd, Winnetka, Illinois 60093 (US). **DELEV, Jordan**; c/o En-

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) Title: METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS

Chemotherapy dose-response study




FIG. 1A

(57) Abstract: Provided herein are methods of treating, preventing, or reducing conditions and/or side effects associated with anti-cancer agents (e.g., chemotherapeutic agents) via administration of a non-naturally occurring melanocortin analog prior to, during, and/or after administration of the anti-cancer agents. The methods reduce adverse effects associated with the anti-cancer agent, such as anorexia, weight loss, muscle mass loss, fat mass loss, wasting, reduced appetite, and loss of appetite, thereby enhancing tolerance of the anti-cancer agents and survival of the subject having cancer or having a disease or condition that is not cancer but is treated, reduced, or prevented by administration of an anti-cancer agent.

[Continued on next page]

WO 2025/151135 A1

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*